BioMarin Reports Q1 Profit Decline Amid Amicus Acquisition Financing and ROCTAVIAN Withdrawal
Summary
BioMarin Pharmaceutical Inc. reported a significant decline in Q1 net income and diluted EPS year-over-year, driven by increased operating expenses and interest costs related to its $4.8 billion Amicus Therapeutics acquisition and the withdrawal of ROCTAVIAN.
Key Events
-
Q1 Profitability Decline
Net income decreased to $105.5 million from $185.7 million year-over-year, with diluted EPS falling to $0.54 from $0.95.
-
Increased Operating Expenses
Cost of sales rose by $43.4 million (including a $31.0 million manufacturing charge), R&D by $20.1 million, and SG&A by $52.2 million.
-
Amicus Acquisition Financing Details
Completed the $4.8 billion Amicus Therapeutics acquisition on April 27, 2026, financed by cash, $850 million in new 2034 notes, and $2.8 billion in new senior secured term loans, increasing total debt to approximately $4.3 billion.
-
ROCTAVIAN Withdrawal Impact
Revenue from ROCTAVIAN decreased significantly due to its voluntary withdrawal from the market, as announced in Q1 2026.
Analysis
BioMarin's first-quarter results reveal a substantial decrease in profitability, with net income falling to $105.5 million from $185.7 million year-over-year and diluted EPS dropping to $0.54 from $0.95. This decline is primarily attributed to a $43.4 million increase in cost of sales (including a $31.0 million charge for a manufacturing issue), a $20.1 million rise in R&D expenses, and a $52.2 million increase in SG&A, partly due to Amicus acquisition pre-close costs. Interest expense also surged due to new debt. While total revenues saw a modest increase, driven by strong performance in VOXZOGO and other enzyme therapies, the voluntary withdrawal of ROCTAVIAN from the market further impacted revenue. The company successfully financed the $4.8 billion Amicus acquisition through cash on hand, $850 million in new senior unsecured notes, and $2.8 billion in new senior secured term loans, significantly increasing its total indebtedness to approximately $4.3 billion. This strategic acquisition is expected to diversify the rare disease portfolio, but investors should monitor the integration and the impact of increased leverage on future profitability.
At the time of this filing, BMRN was trading at $53.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.3B. The 52-week trading range was $50.76 to $66.28. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.